Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

MTNR1B G24E Variant Associates With BMI and Fasting Plasma Glucose in the General Population in Studies of 22,142 Europeans

(2010) E. A. Andersson et al.   DIABETES

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure

(2010) Corby K. Martin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Managing Type 2 Diabetes: Balancing HbA1cand Body Weight

(2010) Annie A. Mavian et al.   POSTGRADUATE MEDICINE

Impact of a Weight Management Program on Health-Related Quality of Life in Overweight Adults With Type 2 Diabetes

(2009) Donald A. Williamson   ARCHIVES OF INTERNAL MEDICINE

Treating diabetes and prediabetes by focusing on obesity management

(2009) Lalita Khaodhiar et al.   Current Diabetes Reports

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis

(2009) A. N. Fabricatore et al.   Obesity Reviews

5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis

(2008) Yong Xu et al.   NEURON

Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women

(2008) Steven R. Smith et al.   Obesity